Open Access'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'
Author(s) -
Nikhil Rabade,
Prashant Tembhare,
Nikhil Patkar,
Pratibha Amare,
Brijesh Arora,
Papagudi Ganesan Subramanian,
Sumeet Gujral
Publication year - 2016
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/0377-4929.188140
Subject(s) - systemic mastocytosis , myeloid leukemia , medicine , minimal residual disease , myeloid , immunology , leukemia , bone marrow
Systemic mastocytosis (SM) with associated clonal nonmast cell lineage disease is seen in up to 20% cases of SM. SM is uncommon in the pediatric population. T (8; 21) (q22; q22) is a good prognostic factor in acute myeloid leukemia (AML). However, the presence of SM confers poor prognosis in t (8; 21) (q22; q22) associated AML. We report the case of a child with t (8; 21) (q22; q22) associated AML with SM and her minimal residual disease status over the course of her treatment. In our case, the abnormal mast cells, showing co-expression of CD25 and CD2, persisted even after the marrow showed no evidence of residual AML.